Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07632742

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Enlarged Prostate (BPH) Benign Prostatic Hyperplasia Genital Diseases Genital Diseases, Male Male Urogenital Diseases Prostatic Diseases Prostatic Hyperplasia Urogenital Diseases

Age range

18 year–100 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern University

Chicago, Illinois, 60611, United States

Location status: Recruiting

Location contact

Alyssa McDonald, MPH

CONTACT

[email protected]

312-695-8146

About this study

The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
  • Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)

Exclusion criteria

  • Patients who lack decisional capacity
  • Patients unable to read/speak English
  • Patients who are on a blood thinner (anticoagulation medication)
  • Patients who do not have internet access to complete postoperative surveys

Treatment and study plan

Magneto 150 holmium laser

Device

The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser

Moses 2.0 holmium laser

Device

The HoLEP procedure will be performed using the Moses 2.0 holmium laser

Primary outcomes

  1. Mean hemostasis time

    Time frame: During surgery

    Overall intraoperative hemostasis time

Secondary outcomes

  1. Mean (average) enucleation time

    Time frame: During surgery

    Time taken to surgically remove excess prostate tissue while leaving the shell of the prostate intact and within the body.

  2. Total operative time

    Time frame: During surgery

    Time taken from official procedure start to completion (not accounting for the time that the patient is wheeled in, prepped and out of the operating room).

  3. Hemostasis efficiency

    Time frame: During surgery

    minutes/gram (prostate tissue removed)

Study contacts

Contact information is provided by the study sponsor or research team.

Alyssa McDonald, MPH

CONTACT

[email protected]

312-695-8146

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • Cook Group Incorporated

Registry information

Official study title

MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jun 8, 2026
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.